Category Archives: Company News

RESI Boston 2017

Fairbanks Pharma CEO Alan Schneyer at RESI Boston
Fairbanks CEO Alan Schneyer at RESI Boston 2017

Fairbanks Pharmaceuticals was selected as a finalist to compete in the RESI Boston 2017 Innovation Challenge. On September 26, Fairbanks Co-Founder and CEO Alan Schneyer presented a poster at RESI, met with potential investors and funding agencies, and networked with angel investors.

The response so far has been very encouraging and has led to a number of follow up conversations.

Fairbanks Recognition: Two Updates

1. Fairbanks Pharmaceuticals was a runner-up in the MilliporeSigma Golden Ticket competition and received an in-kind award from MilliporeSigma.  We thank the judges and organizers and look forward to more competitions this year.
2.  Fairbanks was selected to participate in the Innovation Challenge at RESI Boston by judges at Life Science Nation.  We will be presenting a poster and meeting with potential investors at the meeting in Boston on September 26th.  We look forward to the opportunity to meet investors and Pharma representatives and describe our therapeutic development plan and progress.

Fairbanks is Semifinalist for MilliporeSigma’s Start-Up Program at LabCentral

Fairbanks Pharmaceuticals Inc was selected as a semi-finalist in the competition for MilliporeSigma’s Start-Up program at LabCentral in Cambridge MA. The winner will be awarded a “Golden Ticket” of 1 year of space at one of the country’s leading and highly desirable biotechnology incubators, a fantastic opportunity to move to an environment that fosters partnerships and collaborations that can accelerate our therapeutic development activities.

On August 1, Dr. Alan Schneyer, Fairbanks Co-Founder and CEO, presented Fairbanks’ plans and progress to a highly selective board of judges composed of MilliporeSigma scientists and Lab Central Senior Managers. Results of the judges decision will be announced in mid-August.

Fairbanks Presents at MassCONNECT Final Showcase

Fairbanks Pharmaceuticals presented its unique and innovative approach to attacking the underlying pathology of diabetes by increasing insulin production from existing beta cells and simultaneously inducing regeneration of beta cells at the MassCONNECT Final Showcase on May 18th 2017.  The presentation was met with widespread interest from both pharma and private investors. 

The Final Showcase was the culmination of an eight-week mentorship program with a team of biotech and pharmaceutical industry leaders to help with strategic planning, identifying potential partners and financing, and developing a slide deck. 

MassBio Council MassConnect Program

Fairbanks CEO Alan Schneyer presenting at MassConnect
Fairbanks CEO Alan Schneyer presenting

Alan Schneyer and Elissa Brown gave Fairbanks’ introductory pitch today to MassBio’s 2017 Cycle 1 MassConnect mentors. Fairbanks was one of four biotech startups selected by MassBio to join the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation.

The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital.
MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks.

Click here for more information  on today’s kick-off.

Alan Schneyer (6th from right) and Elissa Brown (3rd from right) with other MassConnect participants

Boehringer-Ingelheim Boston Innovation Prize

(December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks from 30 applicants to compete for their Boston Innovation Prize. BI runs this competition to help sustain innovative pipelines for new breakthrough therapies by providing a Golden Ticket for Lab Central space (valued at $75,000) in Cambridge, MA. The panel of judges includes senior and founding members of Lab Central and BI’s venture capital fund, as well as other seed stage investor groups.